News/ News/ R&D Blow for Novartis as PD-1 drug spartalizumab flunks trial Phil Taylor checkpoint inhibitors, immuno-oncology, Novartis, Oncology, spartalizumab 0 Comment Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed Share X Blow for Novartis as PD-1 drug spartalizumab flunks trial https://pharmaphorum.com/news/blow-for-novartis-as-pd-1-drug-spartalizumab-flunks-trial/